Neurophth Gains $60M For Gene Therapy Efforts

San Diego-based Neurophth, a gene therapy company, has raised $60M in a Series C funding round, the company said today. The funding was co-led by CMG-SDIC Capital and Sequoia Capital China, and also included Sunshine Insurance and China Merchant Bank International Capital. According to the company, the funding will go towards its lead clinical program, enrich R&D pipeline and programs through business development and continue to expand the its gene therapy manufacturing platform. The company has significant operations in China but has its headquarters at Biocom in San Diego.